A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.

Okusaka, Takuji; Morimoto, Manabu; Eguchi, Yuichiro; Nakamura, Shinichiro; Iino, Shuichi; Kageyama, Rie

Okusaka, Takuji; Morimoto, Manabu; Eguchi, Yuichiro; Nakamura, Shinichiro; Iino, Shuichi; Kageyama, Rie.

Afiliação

Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. tokusaka@ncc.go.jp.
Morimoto M; Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Eguchi Y; Liver Center, Saga University Hospital, Faculty of Medicine Saga University, Saga, Japan.
Nakamura S; Loco Medical General Institute, Ogi, Japan.
Iino S; Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kageyama R; Sumitomo Pharma Co., Ltd, Tokyo, Japan.

Drugs R D ; 23(2): 99-107, 2023 Jun.

Article em En | MEDLINE | ID: mdl-37188895

Assuntos

Benzofuranos; Carcinoma Hepatocelular; Neoplasias Hepáticas; Naftoquinonas; Adulto; Humanos; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Carcinoma Hepatocelular/tratamento farmacológico; Carcinoma Hepatocelular/patologia; População do Leste Asiático; Neoplasias Hepáticas/tratamento farmacológico; Neoplasias Hepáticas/patologia; Sorafenibe/uso terapêutico; Naftoquinonas/farmacocinética; Naftoquinonas/uso terapêutico; Benzofuranos/farmacocinética; Benzofuranos/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Benzofuranos / Naftoquinonas / Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google